Testosterone Cypionate and Rosuvastatin Interaction: What Clinicians and Patients Should Know

Why This Combination Comes Up So Often

Men receiving testosterone cypionate for hypogonadism frequently carry concurrent cardiovascular risk factors that call for statin therapy. Hypogonadism itself is associated with metabolic syndrome, and the prevalence of dyslipidemia among men with low testosterone ranges from 40 to 60% in observational cohorts [1]. Rosuvastatin, the most potent single-agent statin by milligram, is one of the most commonly co-prescribed drugs in men starting testosterone replacement therapy (TRT).

The Clinical Scenario

A 48-year-old man with a total testosterone of 220 ng/dL and an LDL-C of 158 mg/dL starts testosterone cypionate 200 mg intramuscularly every two weeks. His internist also prescribes rosuvastatin 10 mg nightly. Six weeks later, his LDL-C has dropped only to 132 mg/dL rather than the expected sub-110 range. The question: is testosterone blunting the statin?

What the Data Suggest

The short answer is yes, partially. Exogenous androgens can shift lipid metabolism in directions that oppose statin therapy, and this pharmacodynamic tension is the central concern with this combination [2]. There is no pharmacokinetic drug-drug interaction that changes blood levels of either drug.

Mechanism of Interaction: Pharmacodynamic, Not Pharmacokinetic

The interaction between testosterone cypionate and rosuvastatin is pharmacodynamic. The two drugs do not compete for the same metabolic enzymes or transporters, but they push lipid biomarkers in opposing directions.

Testosterone's Effect on Lipids

Testosterone cypionate is metabolized primarily by CYP3A4 in the liver [3]. Its effects on lipid metabolism are dose-dependent and route-dependent. Supraphysiologic doses suppress HDL-C more aggressively than physiologic replacement. The FDA-approved label for testosterone cypionate warns that "changes in serum lipid profile may require dose adjustment of lipid-lowering drugs" [3].

A 2017 meta-analysis of 59 randomized controlled trials (N = 3,029) published in The Journal of Clinical Endocrinology & Metabolism found that testosterone therapy reduced HDL-C by a weighted mean of 0.49 mmol/L (approximately 19 mg/dL) and produced variable effects on LDL-C depending on formulation and dose [4]. Injectable formulations like testosterone cypionate showed larger HDL reductions than transdermal gels.

Rosuvastatin's Metabolic Pathway

Rosuvastatin is not significantly metabolized by cytochrome P450 enzymes. Approximately 90% of the drug is eliminated unchanged, primarily through biliary excretion [5]. Its hepatic uptake depends on organic anion-transporting polypeptide 1B1 (OATP1B1) and OATP1B3 transporters. Testosterone does not inhibit or induce these transporters at physiologic or even mildly supraphysiologic concentrations. This means testosterone cypionate does not increase rosuvastatin plasma levels, and the risk of statin-related myotoxicity from a pharmacokinetic interaction is negligible [5].

No CYP450 Conflict

Because rosuvastatin bypasses CYP3A4 metabolism (unlike atorvastatin or simvastatin, which are CYP3A4 substrates), the enzyme overlap is irrelevant here. This is an advantage of rosuvastatin specifically. Had the patient been on simvastatin, CYP3A4 competition from testosterone could theoretically raise statin exposure, though even that scenario lacks strong clinical evidence [6].

Clinical Severity: Moderate, Manageable

Both Lexicomp and Clinical Pharmacology classify this interaction as moderate severity. The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy recommends monitoring lipids at baseline and at 3 to 6 months after initiation, then annually [7]. The American College of Cardiology (ACC) and American Heart Association (AHA) 2018 cholesterol guideline does not specifically address TRT but recommends reassessing statin response when "new factors that may alter the risk-benefit calculation" arise [8].

What "Moderate" Means in Practice

A moderate interaction does not require avoiding the combination. It means prescribers should anticipate a measurable, clinically relevant effect and adjust their monitoring plan. In this case, the prescriber should expect that rosuvastatin's LDL-lowering effect may be attenuated by 5 to 15 percentage points compared with what would be expected in a eugonadal man not receiving exogenous testosterone.

When the Interaction Becomes More Significant

The pharmacodynamic opposition grows more clinically significant in three scenarios: (1) the patient is on supraphysiologic testosterone doses; (2) the patient has familial hypercholesterolemia or very high baseline LDL-C (above 190 mg/dL); or (3) the patient has established atherosclerotic cardiovascular disease (ASCVD) requiring aggressive LDL targets below 70 mg/dL. In these cases, rosuvastatin dose uptitration or addition of ezetimibe may be necessary.

What the TRAVERSE Trial Tells Us

The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men), published in The New England Journal of Medicine in 2023, enrolled 5,246 men aged 45 to 80 with hypogonadism and either established cardiovascular disease or high cardiovascular risk [9]. Participants were randomized to transdermal testosterone gel or placebo and followed for a mean of 33 months.

Key Cardiovascular Findings

TRAVERSE found that testosterone replacement did not increase the incidence of major adverse cardiovascular events (MACE). The hazard ratio for MACE was 0.99 (95% CI, 0.81 to 1.21) [9]. This was reassuring, but it did not specifically stratify outcomes by statin co-use or rosuvastatin specifically.

Lipid Sub-Study Results

In the lipid sub-analysis, men receiving testosterone had a mean HDL-C reduction of 2.1 mg/dL at 12 months compared with placebo, while LDL-C changes did not reach statistical significance in the overall cohort [9]. The modest HDL reduction aligns with physiologic-dose TRT but is smaller than what older studies of injectable testosterone showed, likely because TRAVERSE used transdermal gel rather than intramuscular injections.

Monitoring Protocol for the Combination

A structured monitoring plan prevents this interaction from causing clinical harm.

Baseline (Before Starting TRT)

Obtain a fasting lipid panel, complete metabolic panel, CBC with hematocrit, and PSA. Document the patient's 10-year ASCVD risk score. If the patient is already on rosuvastatin, record the pre-TRT lipid values as the reference point for comparison.

6 to 8 Weeks After TRT Initiation

Recheck the fasting lipid panel. This timing captures the early lipid shift from testosterone before the next routine lab draw. If LDL-C has risen by more than 15% from baseline, consider uptitrating rosuvastatin by one dose step (for example, from 10 mg to 20 mg). If HDL-C has dropped below 30 mg/dL, discuss with the patient whether the testosterone dose can be reduced or the injection interval extended.

Every 6 Months Thereafter

Continue lipid monitoring at 6-month intervals for the first 2 years. Once lipid values are stable on the combination, annual monitoring is reasonable per the Endocrine Society guideline [7]. Always check hematocrit concurrently, as testosterone-induced polycythemia is a separate and more common concern (occurring in approximately 5 to 14% of men on injectable TRT) [10].

When to Add a Second Lipid-Lowering Agent

If rosuvastatin at 40 mg (the maximum approved dose) fails to achieve the patient's LDL-C target, adding ezetimibe 10 mg is the next step. This combination achieves an additional 20 to 25% LDL-C reduction beyond maximal statin therapy [11]. For patients with established ASCVD who cannot reach an LDL-C below 70 mg/dL, a PCSK9 inhibitor (evolocumab or alirocumab) is the guideline-recommended escalation.

Dose Adjustment Considerations

Routine dose adjustment of either testosterone cypionate or rosuvastatin is not required solely because the two drugs are co-prescribed. Adjustments are driven by lab results.

Testosterone Dose

The Endocrine Society recommends targeting a total testosterone level of 450 to 600 ng/dL on trough draws [7]. If a patient's lipids worsen significantly after starting TRT, consider whether the testosterone dose is producing supraphysiologic levels. A trough testosterone above 700 ng/dL on a standard 200 mg every-two-weeks regimen suggests the dose is too high. Reducing to 150 mg or switching to weekly 100 mg injections (which produce more stable levels) may reduce the lipid impact.

Rosuvastatin Dose

The JUPITER trial (N = 17,802) demonstrated that rosuvastatin 20 mg reduced LDL-C by a median of 50% and reduced the primary cardiovascular endpoint by 44% (HR 0.56; 95% CI, 0.46 to 0.69) [12]. If a patient on TRT is not achieving an adequate LDL-C reduction, the first question is adherence. The second is whether testosterone is the confounding variable. A structured dose-response assessment, holding the testosterone dose stable and uptitrating rosuvastatin, clarifies the answer.

Myopathy Risk: Low but Worth Discussing

Rosuvastatin carries a class-wide statin warning for myopathy and rhabdomyolysis. Testosterone, independently, can cause musculoskeletal complaints and elevated creatine kinase (CK) levels from anabolic effects on muscle tissue. This creates a diagnostic challenge.

Distinguishing Testosterone-Related CK Elevation from Statin Myopathy

The 2019 European Atherosclerosis Society (EAS) consensus statement on statin-associated muscle symptoms notes that CK elevations up to 4 times the upper limit of normal (ULN) without symptoms do not require statin discontinuation [13]. In men on TRT who exercise vigorously, CK can rise from both the anabolic effect of testosterone and from exercise itself. A CK level that is 3 to 5 times ULN in an asymptomatic patient on TRT and rosuvastatin should prompt a repeat measurement at rest before attributing it to the statin.

If the patient reports muscle pain, weakness, or dark urine, hold rosuvastatin immediately and check CK and renal function. Testosterone does not need to be stopped unless rhabdomyolysis is confirmed, since testosterone is not a direct contributor to statin myotoxicity through pharmacokinetic mechanisms.

Patient Counseling Points

Patients should understand three things about this combination.

First, both medications are safe to take together, but the combination requires more frequent blood work than either drug alone. Second, testosterone can raise cholesterol, which might mean the statin dose needs to increase over time. Third, any unexplained muscle pain, tenderness, or brown-colored urine while on both medications should be reported to the prescribing clinician immediately rather than managed with over-the-counter anti-inflammatory drugs.

The Endocrine Society guideline states: "Clinicians should monitor lipid profiles in all men receiving testosterone therapy, particularly those with pre-existing cardiovascular risk factors" [7]. The ACC/AHA cholesterol guideline reinforces that "statin therapy intensity should be adjusted based on percentage reduction in LDL-C and patient-specific risk" [8].

Special Populations

Older Men (Over 65)

Men over 65 are more susceptible to statin myopathy [13]. They also metabolize testosterone more slowly, producing higher peak levels on standard doses. Starting rosuvastatin at 5 mg and testosterone cypionate at 100 mg weekly (rather than 200 mg biweekly) reduces the risk profile.

Men with Hepatic Impairment

Both testosterone cypionate and rosuvastatin carry hepatic precautions. Rosuvastatin is contraindicated in patients with active liver disease or unexplained persistent transaminase elevations [5]. Testosterone cypionate may cause peliosis hepatis in rare cases, though this is more associated with oral 17-alpha-alkylated androgens [3]. In men with mild hepatic impairment (Child-Pugh A), the combination can be used with liver function monitoring at 4-week intervals for the first 3 months.

Men with Renal Impairment

Rosuvastatin requires dose adjustment in severe renal impairment (eGFR <30 mL/min/1.73 m²), with a maximum dose of 10 mg [5]. Testosterone cypionate does not require renal dose adjustment but may worsen fluid retention in men with compromised kidney function.